The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting a strategic pivot toward high-growth medical technologies, AngioDynamics reported fourth-quarter results that beat expectations on both lines, posting an adjusted loss per share of -$0.07 against a projected -$0.11. Revenue reached $86.61 million, surpassing the $80.24 million consensus, fueled by explosive growth in key platforms as NanoKnife sales surged 64.5% and AlphaVac grew by 38.4%.
Following the report, H.C. Wainwright raised its price target for ANGO to $19 from $16 while maintaining a Buy rating, helping the stock hit a new 52-week high of $14.80. Per market data, this momentum highlights the company's successful focus on interventional oncology, which has allowed it to capture market share from larger peers despite the broader industry's rising operating costs and inflationary pressures.
Looking ahead, the company's fiscal year 2027 sales guidance of $336 million to $341 million serves as a critical catalyst for valuation expansion. Investors should monitor the stock's ability to hold its recent highs, while also watching the U.S. Federal Reserve's Monetary Policy Report on July 10, 2026, for insights into the interest rate environment affecting growth-stage med-tech firms.